131 related articles for article (PubMed ID: 38219557)
1. Synthetic studies on the extracellular domain of the T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) using Trt-K
Iwamoto N; Sasaki J; Ohno S; Aoki K; Usui Y; Inuki S; Ohno H; Oishi S
Bioorg Med Chem; 2024 Feb; 99():117585. PubMed ID: 38219557
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of signal regulatory protein alpha and T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain expression in undifferentiated pleomorphic sarcoma.
Ishihara S; Iwasaki T; Kohashi K; Kawaguchi K; Toda Y; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Oda Y
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2425-2436. PubMed ID: 35737088
[TBL] [Abstract][Full Text] [Related]
3. Gene of the month: T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT).
Bolm L; Petruch N; Sivakumar S; Annels NE; Frampton AE
J Clin Pathol; 2022 Apr; 75(4):217-221. PubMed ID: 35058314
[TBL] [Abstract][Full Text] [Related]
4. TgMab-2: An Anti-human T Cell Immunoglobulin and Immunoreceptor Tyrosine-Based Inhibitory Motif Domain Monoclonal Antibody for Immunocytochemistry.
Saito M; Suzuki H; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2022 Jun; 41(3):157-162. PubMed ID: 35736625
[TBL] [Abstract][Full Text] [Related]
5. CD155 mutation (Ala67Thr) increases the binding affinity for and the signaling via an inhibitory immunoreceptor TIGIT.
Matsuo T; Iguchi-Manaka A; Shibuya A; Shibuya K
Cancer Sci; 2022 Nov; 113(11):4001-4004. PubMed ID: 35947095
[TBL] [Abstract][Full Text] [Related]
6. Expression of T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain on CD4
Kurita M; Yoshihara Y; Ishiuji Y; Chihara M; Ishiji T; Asahina A; Yanaba K
J Dermatol; 2019 Jan; 46(1):37-42. PubMed ID: 30402886
[TBL] [Abstract][Full Text] [Related]
7. TIGIT Can Exert Immunosuppressive Effects on CD8+ T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro.
Zhang C; Wang Y; Xun X; Wang S; Xiang X; Hu S; Cheng Q; Guo J; Li Z; Zhu J
J Immunother; 2020 Oct; 43(8):236-243. PubMed ID: 32804915
[TBL] [Abstract][Full Text] [Related]
8. T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain as a promising immune checkpoint target for the treatment of SLE.
Zhao J; Li L; Feng X; Fan X; Yin H; Lu Q
Lupus; 2024 Mar; 33(3):209-216. PubMed ID: 38291414
[TBL] [Abstract][Full Text] [Related]
9. Generation and characterization of polyclonal antibodies against mouse T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory domain by DNA-based immunization.
Gao Y; Cui J; He W; Yue J; Yu D; Cai L; Xu H; Yang C; Chen ZK; Zhou H
Transplant Proc; 2014; 46(1):260-5. PubMed ID: 24507063
[TBL] [Abstract][Full Text] [Related]
10. Targeting TIGIT for cancer immunotherapy: recent advances and future directions.
Zhang P; Liu X; Gu Z; Jiang Z; Zhao S; Song Y; Yu J
Biomark Res; 2024 Jan; 12(1):7. PubMed ID: 38229100
[TBL] [Abstract][Full Text] [Related]
11. Expression of T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT) in anaplastic thyroid carcinoma.
Nakazawa T; Nagasaka T; Yoshida K; Hasegawa A; Guo F; Wu D; Hiroshima K; Katoh R
BMC Endocr Disord; 2022 Aug; 22(1):204. PubMed ID: 35971106
[TBL] [Abstract][Full Text] [Related]
12. [Research Progress of Immune Checkpoint TIGIT in Lung Cancer Immunotherapy].
Wu J; Ren D; Bi H; Yi B; Wang H
Zhongguo Fei Ai Za Zhi; 2022 Nov; 25(11):819-827. PubMed ID: 36419396
[TBL] [Abstract][Full Text] [Related]
13. Immune Exhaustion of T Cells in Alveolar Echinococcosis Patients and Its Reversal by Blocking Checkpoint Receptor TIGIT in a Murine Model.
Zhang C; Lin R; Li Z; Yang S; Bi X; Wang H; Aini A; Zhang N; Abulizi A; Sun C; Li L; Zhao Z; Qin R; Li X; Li L; Aji T; Shao Y; Vuitton DA; Tian Z; Wen H
Hepatology; 2020 Apr; 71(4):1297-1315. PubMed ID: 31410870
[TBL] [Abstract][Full Text] [Related]
14. TIGIT and CD155 as Immune-Modulator Receptor and Ligand on CD4
Kamrani A; Soltani-Zangbar MS; Shiri S; Yousefzadeh Y; Pourakbari R; Aghebati-Maleki L; Mehdizadeh A; Danaii S; Jadidi-Niaragh F; Yousefi B; Kafil HS; Hojjat-Farsangi M; Motavalli R; Zolfaghari M; Haji-Fatahaliha M; Mahmoodpoor A; Ahmadian Heris J; Emdadi A; Yousefi M
Immunol Invest; 2022 May; 51(4):1023-1038. PubMed ID: 33855917
[TBL] [Abstract][Full Text] [Related]
15. Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis.
Ozmadenci D; Shankara Narayanan JS; Andrew J; Ojalill M; Barrie AM; Jiang S; Iyer S; Chen XL; Rose M; Estrada V; Molinolo A; Bertotto T; Mikulski Z; McHale MC; White RR; Connolly DC; Pachter JA; Kuchroo VK; Stupack DG; Schlaepfer DD
Proc Natl Acad Sci U S A; 2022 Apr; 119(17):e2117065119. PubMed ID: 35467979
[TBL] [Abstract][Full Text] [Related]
16. TIGIT: An emerging immune checkpoint target for immunotherapy in autoimmune disease and cancer.
Zhao J; Li L; Yin H; Feng X; Lu Q
Int Immunopharmacol; 2023 Jul; 120():110358. PubMed ID: 37262959
[TBL] [Abstract][Full Text] [Related]
17. T-cell Immunoglobulin and ITIM Domain Contributes to CD8
Song Y; Wang B; Song R; Hao Y; Wang D; Li Y; Jiang Y; Xu L; Ma Y; Zheng H; Kong Y; Zeng H
Aging Cell; 2018 Apr; 17(2):. PubMed ID: 29349889
[TBL] [Abstract][Full Text] [Related]
18. DNAM-1 versus TIGIT: competitive roles in tumor immunity and inflammatory responses.
Shibuya A; Shibuya K
Int Immunol; 2021 Nov; 33(12):687-692. PubMed ID: 34694361
[TBL] [Abstract][Full Text] [Related]
19. CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y
Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677
[TBL] [Abstract][Full Text] [Related]
20. TIGIT and PD-1 may serve as potential prognostic biomarkers for gastric cancer.
Xu D; Zhao E; Zhu C; Zhao W; Wang C; Zhang Z; Zhao G
Immunobiology; 2020 May; 225(3):151915. PubMed ID: 32122675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
